Literature DB >> 2881041

Serological response to the hepatitis delta virus in hepatitis D.

M Aragona, S Macagno, F Caredda, O Crivelli, C Lavarini, E Maran, P Farci, R H Purcell, M Rizzetto.   

Abstract

Sera from 74 hepatitis B surface antigen-positive individuals, who presented with acute hepatitis delta virus (HDV) infection which ran a self-limited course in 58 and progressed to chronicity in 16, were tested over time for HDV markers. In self-limited disease the serum pattern varied from early HD-antigenaemia followed by IgM and IgG anti-HD seroconversion, to the appearance of IgM and IgG anti-HD without antigenaemia, or the isolated expression of either the IgM or the IgG antibody. The typical case of IgM anti-HD was transient and appeared with a mean delay of 10-15 days from admission in the different serological subgroups. The IgG antibody usually developed several weeks later during convalescence. In contrast, patients with disease destined to become chronic had a brisk IgM antibody response and IgG anti-HD was detectable with a mean delay of 15 days; generally, the IgM and the IgG antibody persisted over the follow-up time. IgM antibody to HDV is often the only serological test positive in the clinical stage of hepatitis D and repeated testing for this marker is necessary to diagnose acute HDV co-infection. The serological follow-up provides important prognostic information: waning of IgM confirms resolution of HDV infection, persistence predicts chronicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881041     DOI: 10.1016/s0140-6736(87)92090-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Evaluation of enzyme immunoassays for detection of delta antigen and antibody.

Authors:  A G Shattock; M Morris
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

2.  Acute delta hepatitis during treatment with adenosine arabinoside monophosphate with resolution of the HBsAg carrier state.

Authors:  G Garcia; A Smedile; K F Bergmann; J L Gerin; P B Gregory; T C Merigan; W S Robinson
Journal:  West J Med       Date:  1990-07

Review 3.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

4.  Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies.

Authors:  A G Shattock; M C Morris
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

Review 5.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Kinetics of delta antigen and delta antibody in acute delta hepatitis: evaluation with different enzyme immunoassays.

Authors:  F Dubois; A Goudeau
Journal:  J Clin Microbiol       Date:  1988-07       Impact factor: 5.948

Review 7.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 8.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

Review 9.  Viral Hepatitis Other than A, B, and C: Evaluation and Management.

Authors:  Amanda Cheung; Paul Kwo
Journal:  Clin Liver Dis       Date:  2020-04-13       Impact factor: 6.126

10.  High prevalence of hepatitis delta virus in Cameroon.

Authors:  Emily K Butler; Mary A Rodgers; Kelly E Coller; Devin Barnaby; Elizabeth Krilich; Ana Olivo; Michael Cassidy; Dora Mbanya; Lazare Kaptue; Nicaise Ndembi; Gavin Cloherty
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.